Date receipt dossier
EudraCT number
2009-012973-37
Company / Sponsor
Molmed S.p.A.
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
Acute leukemia
Therapeutic approach
Restore immunity + treatment of GVHD
Genetic modification
-Thymidine Kinase (HSV-Tk)
- selection marker
- selection marker
Method of transfer of nucleic acid of interest
Moloney Murine Leukemia virus
Administered biological material
haploidentical donor T-lymphocytes expressing HSV-Tk
Route of administration
Intravenous
Locations in Belgium
UZ Leuven - AZ St Jan, Brugge - CHU Liège
Type of procedure
Contained use only
Pharmaceutical study code
IPR/21-TK008